Angiotensin II type 1 receptor antagonism improves endothelial vasodilator function in L-NAME-induced hypertensive rats by a kinin-dependent mechanism

Journal of Hypertension

Volumn 24, Issue 1, 2006, Pages 95-102

  De Gennaro Colonna, Vito ^a   Fioretti, Simona ^a   Rigamonti, Antonello ^a   Bonomo, Sara ^a   Manfredi, Barbara ^a   Muller, Eugenio E ^a   Berti, Ferruccio ^a   Rossoni, Giuseppe ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiotensin II type 1 receptor antagonists; Bradykinin; Endothelial dysfunction; Hypertension; Nitric oxide

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ICATIBANT; KININ; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRITE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD LEVEL; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; EVALUATION; GENE EXPRESSION; HYPERTENSION; MALE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

EID: 29144466796     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000194116.89356.66     Document Type: Article

References (36)

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
2. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. THE TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94:258-265.
3. Rizzoni D, Muiesan ML, Porteri E, Castellano M, Zulli R, Bettoni G, et al. Effects of long-term antypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997; 15:197-204.
4. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patirnts with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103:799-805.
5. Kung CF, Moreau P, Takase H, Luscher TF. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. Hypertension 1995; 26:744-751.
6. Takase H, Moreau P, Kung CF, Nava E, Luscher TF. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 1996; 27:25-31.
7. Cheetam C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000; 36:1461-1466.
8. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101:2349-2354.
9. Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Linz W, et al. Long-term low-dose angiotensin converting inhibitor treatment increases vascular cyclic guanosine 3′,5′-monophosphate. Hypertension 1993; 22:682-687.
10. Barbe F, Su JB, Guyene TT, Crozatier B, Menard J, Hittinger L. Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. Am J Physiol 1996; 270:H1985-H1992.
11. Su JB, Barbe F, Remi H, Guyene TT, Crozatier B, Hittinger L. Preserved vasodilatoreffect of bradykinin in dogs with heart failure. Circulation 1998; 98:2911-2918.
12. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95:1115-1118.
13. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
14. Gohlke P, Pees C, Unger T. AT2 raceptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31:349-355.
15. Searles CD, Harrison DG. The interaction of nitric oxide, bradykinin, and angiotensin II type 2 receptor: lessons learned from transgenic mice. J Clin Invest 1999; 104:1013-1014.
16. Tsutsumi Y, Matsubara H, Kurihara H, Murasawa S, Takai S, Miyazaki M, et al. Angiotensin II type 2 overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104:925-935.
17. De Gennaro Colonna V, Rossoni G, Rigamonti AE, Bonomo S, Manfredi B, Berti F, et al. Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol 2002; 450:61-66.
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
19. Hattori Y, Akimoto K, Murakami Y, Kasai K. Pyrrolidine dithiocarbamate inhibits cytokine-induced VCAM-1 gene expression in rat cardiac myocytes. Mol Cell Biochem 1997; 177:177-181.
20. Kobayashi N, Kobayashi K, Hara K, Higashi T, Yanaka H, Yagi S, et al. Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats. Am J Hypertens 1999; 12:483-491.
21. 15N nitrate in biological fluids. Anal Biochem 1982; 126:131-138.
22. Pradelles P, Grassi J, MacLouf J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985; 57:1170-1173.
23. Ribeiro MO, Antunes E, Nicci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992; 20:298-303.
24. Kobayashi N, Kazuoyoshi H, Hara K, Higashi T, Yanaka H, Yagi S, Matsuoka H. Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA. Am J Hypertens 2000; 13:199-207.
25. Gohlke P, Linz W, Scholkens BA, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996; 28:397-402.
26. Krishnankutty S, MacGregor JS, Gupta M, Barbant SD, Redberg R, Yock PG, et al. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Circulation 1993; 87:931-938.
27. Maeso R, Rodrigo E, Munoz-Garcia R, Navarro-Cid J, Ruilope LM, Cachoifero V, et al. Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. J Hypertens 1998; 16:665-672.
28. Riveiro A, Mosquera A, Alonso M, Calvo C. Angiotensin II type 1 receptor blocker irbesartan ameliorates vascular function in spontaneously hypertensive rats regardless of oestrogen status. J Hypertens 2002; 20:1385-1372.
29. Hornig B, Kohler C, Schink D, Tatge H, Drexler H. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism. Hypertension 2003; 41:1092-1095.
30. Thai H, Wollmuth J, Goldman S, Gaballa M. Angiotensin subtype 1 receptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther 2003; 307:1171-1178.
31. Higashi T, Kobayashi N, Hara K, Shirataki H, Matsuoka H. Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodelling in goldblatt hypertensive rats. J Cardiovasc Pharmacol 2000; 35:564-571.
32. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995; 26:233-240.
33. Tschope C, Schultheiss H-P, Walther T. Multiple interactions between the renin angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 2002; 39:478-487.
34. Linz W, Wiemer G, Scholkens BA. ACE-inhibition induces no inflammation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol 1992; 24:909-917.
35. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium derived bradykinin. Hypertension 1991; 18:558-563.
36. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 2003; 42:600-604.